Compare SOAR & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SOAR | NXL |
|---|---|---|
| Founded | 2021 | 2010 |
| Country | United States | United States |
| Employees | 13 | 8 |
| Industry | Blank Checks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3M | 10.2M |
| IPO Year | N/A | N/A |
| Metric | SOAR | NXL |
|---|---|---|
| Price | $0.17 | $0.35 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 25.7M | 212.4K |
| Earning Date | 05-15-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $15.52 |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | $0.28 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.12 | $0.31 |
| 52 Week High | $4.36 | $2.00 |
| Indicator | SOAR | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 44.43 | 38.49 |
| Support Level | $0.12 | $0.35 |
| Resistance Level | $0.27 | $0.46 |
| Average True Range (ATR) | 0.02 | 0.04 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 22.42 | 11.81 |
Volato Group Inc is an aviation technology company that connects travelers to private, on-demand flight access and develops proprietary software platforms for enterprise and operational applications. The company operates in a single operating and reportable segment, private aviation services. It operates an aircraft ownership program, provides ad-hoc charter flights, sells deposit products, and manages aircraft for owners in the private aviation industry. It offers fractional ownership, aircraft management, jet cards, deposit, and charter programs. The company's fractional programs provides flexible hours and a revenue share for owners in a fleet of HondaJets, optimized for missions of up to four passengers.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.